Keyword: Impax Laboratories
Impax CEO Fred Wilkinson is departing the company, to be replaced by board member J. Kevin Buchi on an interim basis.
Generics makers lost $8.5 billion in value Thursday on news that the feds are prepping price-fixing charges against industry players. The good news: Though the danger is real--and quite significant--analysts figure it will be confined to only a few of the 12 companies that have received federal subpoenas.
Some analysts think Mylan may not escape lasting impact from the EpiPen pricing controversy. The way they see it, the FDA is under intense pressure to approve competing products--Teva’s for one--and other players like Impax Laboratories are positioning themselves to snatch away market share.
Impax Laboratories has again been tripped up by labeling issues on a drug and is retrieving a lot of a med for treating epilepsy or bipolar disorders in its most recent recall.
Fresh off dropping $130 million to license AstraZeneca's Zomig, drug delivery firm Impax Pharmaceuticals faces a citation from the FDA for its manufacturing practices.